ANGIOGENESIS: A KEY TARGET IN ONCOLOGY - Barcelona, Spain, 25-26 April 2008
FRIDAY, 25 April 2008
13:30-13:40 Introduction - Eric Van Cutsem, Emile Voest, Matti Aapro
13.40-14:15 The Judah Folkman Lecture: changing perspectives on the development of tumor neovasculature - Emile Voest
Session I: Understanding angiogenesis – Clinically relevant basic data
14:15-14:35 Signaling pathways in endothelial cells - Luisa Arispe, UCLA, USA
14:45-15:05 How can we interfere with the process of angiogenesis? - Peter Carmeliet, Leuven, BE
Session II: Angiogenesis in the clinic
15:45-16:05 Angiogenesis inhibitors in breast cancer - Nadia Harbeck, Munich, GE
16:15-16:35 Angiogenesis inhibitors in colon cancer - Eric Van Cutsem, Leuven, BE
16:45-17:05 Angiogenesis inhibitors in pancreatic cancer and in neuroendocrine tumors - James Yao, Houston, TX, USA
17:15-17:45 Clinical case studies - Chairman & course coordinator
SATURDAY April 26
Session III: Clinical Usage of angiogenesis inhibitors
08:30-08:50 Imaging for angiogenesis inhibitors - Gordon Jayson, Manchester, UK
09:00-09:20 Surgery after angiogenesis inhibitors - Thomas Grünberger, Vienna, Austria
09:30-09:50 Can we combine angiogenesis inhibitors with radiotherapy - Karin Haustermans, Leuven, BE
10:00-10:20 Panel discussion
Session IV: Clinical Usage in Other Cancers
11:15-11:35 The role of anti-angiogenesis agents in the treatment of NSCLC - Chandra Belani, Pittsburgh, USA
11:45-12:05 Angiogenesis-inhibitors in hepatocellular cancer - Michel Ducreux, Villejuif, France
12:15-12:35 Positioning anti-angiogenic agents in renal cell carcinoma - Joaquim Bellmunt, Barcelona, Spain
12:45-13:05 Gastric Cancer – how to position anti-angiogenic drugs - Josep Tabernero, Barcelona, Spain
13:15-13:45 How to go forward from here? What brings us the future? - Luisa Arispe, Emile Voest, Eric van Cutsem
